Maio'17
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators..


Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO.

 
Agenda
18 de Novembro de 2017 Lisboa
2º Curso Janssen F.I.R.S.T.
De 18 de Janeiro a 20 de Janeiro de 2018 Lisboa
Reunião Anual
De 14 de Fevereiro a 15 de Fevereiro de 2018 Viena
16th IBD Intensive Advanced Course
©2017 GEDII - Grupo de Estudos da Doença Inflamatória Intestinal | Todos os direitos reservados | Links úteis
Desenvolvido por DogmaSis